Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

What's Next For NRx Pharma As FDA Denies Breakthrough Therapy Tag For COVID-19 Therapy

  • The FDA has denied NRx Pharmaceuticals Inc's (NASDAQ:NRXP) Breakthrough Therapy designation (BTD) request for Zyesami (aviptadil).
  • The request for BTD was submitted based on a post-hoc subgroup analysis of patients who, in addition to aviptadil or placebo, were also treated with Gilead Sciences Inc's (NASDAQ: GILD) remdesivir and whose respiratory failure due to critical COVID-19 continued to progress.
  • Related: Why NRX Pharmaceuticals Shares Are Trading Lower During Premarket On Thursday?
  • The company emphasized its focus on the company's NRX-101 BTD compound for Bipolar Depression associated with Suicidality.
  • It expects topline data from the Phase 2 study of NRX-101 in patients with bipolar depression with sub-acute suicidal ideation (SSIB) by the end of the year. 
  • "Given ZYESAMI's mechanism and its well-characterized safety profile, NRx Pharmaceuticals will further evaluate the options for its use in other high unmet pulmonary and non-pulmonary indications," said Robert Besthof, interim CEO of NRx Pharma. 
  • Price Action: NRXP shares are down 0.85% at $0.57 during the premarket session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.